ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE)

PRESS RELEASE

published on 08/25/2025 at 07:00, 8 months 15 days ago

OSE Immunotherapeutics Propose une Evolution de sa Gouvernance et Réaffirme ses Priorités Stratégiques à l’Approche de son Assemblée Générale Annuelle
OSE Immunotherapeutics propose une évolution de sa gouvernance et réaffirme ses priorités stratégiques. Assemblée Générale Annuelle le 30 septembre 2025 à Paris

Gouvernance Évolution Assemblée Générale Annuelle Priorités Stratégiques OSE Immunotherapeutics
PRESS RELEASE

published on 08/25/2025 at 07:00, 8 months 15 days ago

OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting
OSE Immunotherapeutics announces proposed governance evolution and reaffirms strategic priorities ahead of Annual General Meeting. Company focuses on Tedopi® and Lusvertikimab to unlock full potential

Strategic Priorities Governance Evolution OSE Immunotherapeutics Lusvertikimab Tedopi
BRIEF

published on 08/20/2025 at 18:05, 8 months 20 days ago

OSE Immunotherapeutics Appoints Thomas Gidoin as CFO

Chief Financial Officer Strategic Planning Biotech Financing OSE Immunotherapeutics Thomas Gidoin
BRIEF

published on 08/20/2025 at 18:05, 8 months 20 days ago

OSE Immunotherapeutics nomme Thomas Gidoin au poste de directeur financier

Directeur Financier Planification Stratégique OSE Immunotherapeutics Financement Des Biotechnologies Thomas Gidoin
PRESS RELEASE

published on 08/20/2025 at 18:00, 8 months 20 days ago

OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
OSE Immunotherapeutics appoints Thomas Gidoin as Chief Financial Officer, bringing deep expertise in capital markets and financial strategy to the company. Gidoin succeeds Anne-Laure Autret-Cornet

Chief Financial Officer Capital Markets Financial Strategy OSE Immunotherapeutics Thomas Gidoin
PRESS RELEASE

published on 08/20/2025 at 18:00, 8 months 20 days ago

OSE Immunotherapeutics nomme Thomas Gidoin au poste de Directeur Financier
Nomination de Thomas Gidoin comme nouveau Directeur Financier chez OSE Immunotherapeutics. Il apporte 15 ans d'expertise internationale en finance et gouvernance

Biotechnologie Finance Directeur Financier OSE Immunotherapeutics Thomas Gidoin
BRIEF

published on 07/02/2025 at 08:05, 10 months 7 days ago

OSE Immunotherapeutics Updates on Legal Proceedings

Transparency Shareholder Meeting Legal Proceedings OSE Immunotherapeutics Nantes Commercial Court
BRIEF

published on 07/02/2025 at 08:05, 10 months 7 days ago

Mises à jour d'OSE Immunotherapeutics sur les procédures judiciaires

Transparence Assemblée Des Actionnaires OSE Immunotherapeutics Procédures Judiciaires Tribunal De Commerce De Nantes
PRESS RELEASE

published on 07/02/2025 at 08:00, 10 months 7 days ago

OSE Immunotherapeutics met à jour l’information sur les procédures en cours
OSE Immunotherapeutics provides an update on ongoing legal proceedings regarding shareholders' motions, confirms plans for annual shareholders' meeting on September 30, 2025

Shareholders Biotech Annual Meeting Legal Proceedings OSE Immunotherapeutics
PRESS RELEASE

published on 07/02/2025 at 08:00, 10 months 7 days ago

OSE Immunotherapeutics met à jour l’information sur les procédures en cours
Mise à jour des procédures en cours par OSE Immunotherapeutics concernant une action en justice et la tenue de leur assemblée générale annuelle. Vision prospective de l'entreprise

Biotechnologie Procédures En Cours Déclarations Prospectives Assemblée Générale Annuelle OSE Immunotherapeutics

Published on 05/09/2026 at 01:55, 18 hours 14 minutes ago

Prospect Ridge Announces Board Resignation
Published on 05/09/2026 at 01:40, 18 hours 29 minutes ago

Findev Inc. Issues Corrective Disclosure
Published on 05/09/2026 at 01:30, 18 hours 39 minutes ago

Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 20 hours 9 minutes ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:01, 21 hours 8 minutes ago

Water Ways Announces Corporate Updates

View all ACCESSWIRE

Published on 05/09/2026 at 19:05, 1 hour 4 minutes ago

LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 23 hours 31 minutes ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 1 day ago

EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 1 day 1 hour ago

Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/08/2026 at 18:29, 1 day 1 hour ago

Designated Person Notification

View all EQS

Published on 05/07/2026 at 19:15, 2 days ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 2 days ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 2 days 1 hour ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 2 days 1 hour ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 2 days 1 hour ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE

News